Sibnayal is a medicine used to treat patients from the age of one year with distal renal tubular acidosis (dRTA), a disease in which the kidneys do not remove acid through the urine well enough. This results in a build-up of acid in the blood, which leads to a range of symptoms including hearing and growth problems, vomiting, kidney stones and lack of alertness. The disease also causes levels of potassium in the blood to fall, which can lead to muscle weakness and paralysis. Sibnayal contains the active substances potassium citrate and potassium hydrogen carbonate.
Therapeutic Indication
### Therapeutic indication Sibnayal is indicated for the treatment of distal renal tubular acidosis (dRTA) in adults, adolescents and children aged one year and older.
Therapeutic Area (MeSH)
ATC Code
A12BA30
ATC Item
potassium (different salts in combination)
Pharmacotherapeutic Group
Mineral supplements
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| potassium citrate monohydrated | N/A | potassium citrate monohydrated |
| potassium hydrogen carbonate | N/A | Potassium bicarbonate |
| Potassium citrate monohydrated | N/A | potassium citrate monohydrated |
| Potassium hydrogen carbonate | N/A | Potassium bicarbonate |
EMA Name
Sibnayal
Medicine Name
Sibnayal
Aliases
N/A